Published in Clin Cancer Res on April 01, 2007
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77
MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep (2008) 1.57
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica (2011) 1.46
MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One (2012) 1.45
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 1.44
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol (2012) 1.33
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia (2011) 1.26
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res (2010) 1.14
Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer (2010) 1.11
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One (2012) 1.07
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer (2011) 1.06
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol (2009) 1.06
PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res (2010) 1.06
Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer (2012) 1.06
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis (2012) 0.98
The MET axis as a therapeutic target. Update Cancer Ther (2009) 0.98
NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene (2011) 0.97
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer (2015) 0.93
Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met. J Invest Dermatol (2010) 0.92
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res (2013) 0.92
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther (2008) 0.92
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PLoS One (2013) 0.91
Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget (2013) 0.89
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther (2014) 0.88
Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med (2011) 0.87
Biology of MET: a double life between normal tissue repair and tumor progression. Ann Transl Med (2015) 0.86
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs (2014) 0.85
Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) (2007) 0.85
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer (2013) 0.84
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell Melanoma Res (2009) 0.84
PAX3 and ETS1 synergistically activate MET expression in melanoma cells. Oncogene (2014) 0.83
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One (2014) 0.82
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget (2016) 0.81
c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One (2012) 0.80
Promise and challenges on the horizon of MET-targeted cancer therapeutics. World J Biol Chem (2015) 0.80
Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Cell Death Differ (2016) 0.79
Systemic therapy of non-resectable metastatic melanoma. Cancers (Basel) (2010) 0.78
Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg (2012) 0.78
SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget (2016) 0.78
Knockdown of the fat mass and obesity gene disrupts cellular energy balance in a cell-type specific manner. PLoS One (2012) 0.77
T-oligo as an anticancer agent in colorectal cancer. Biochem Biophys Res Commun (2014) 0.75
MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. Oncotarget (2017) 0.75
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer (2017) 0.75
Human papillomavirus type 16 E6 suppresses microRNA-23b expression in human cervical cancer cells through DNA methylation of the host gene C9orf3. Oncotarget (2017) 0.75
Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma. Cancers (Basel) (2015) 0.75
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res (2017) 0.75
MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget (2017) 0.75
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int J Mol Sci (2017) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol (2004) 3.08
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res (2006) 2.84
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J (2009) 2.82
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging. J Am Coll Cardiol (2004) 2.50
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer (2007) 2.31
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
BAP1 and cancer. Nat Rev Cancer (2013) 2.23
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol (2010) 2.20
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology (2009) 2.02
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 1.99
Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther (2006) 1.92
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2009) 1.85
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med (2012) 1.76
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 1.71
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology (2010) 1.70
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Primary benign vascular tumors and tumorlike lesions of the kidney: a clinicopathologic analysis of 15 cases. Virchows Arch (2012) 1.67
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest (2008) 1.64
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59
Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol (2008) 1.56
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem (2007) 1.53
Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A (2009) 1.52
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.51
High molecular weight polyethylene glycol (PEG 15-20) maintains mucosal microbial barrier function during intestinal graft preservation. J Surg Res (2013) 1.51
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep (2007) 1.50
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med (2006) 1.47
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg (2010) 1.46
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem (2001) 1.45
Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer (2013) 1.45
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol (2011) 1.45
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res (2008) 1.33
Lung carcinoma in African Americans. Nat Clin Pract Oncol (2007) 1.33
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem (2010) 1.27
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26